V8 Peptides Review: Pricing, COAs, Testing, and What We Found
Our independent V8 Peptides review checks Accumark reports, exact tested strengths, fragment identities, single-vial prices, and the corrected TB-500 listing.
We reviewed V8 Peptides, its complete published catalog and certificate library, and the corresponding Accumark Labs records on October 29, 2026. The laboratory documents were independently checkable. The main limitations were incomplete coverage of labeled sizes and the need to distinguish different thymosin beta-4 fragments.
Updated November 2, 2026: V8 corrected its standalone TB-500 specification, so that price now joins the 17–23 fragment comparison group. The new report names Palmetto Peptides LLC and adds no V8 testing credit pending a confirmed lot relationship. See the re-review below; the original catalog and testing figures retain their October 29 scope.
This is a free independent evaluation. Relationship update, October 29, 2026: PeptideBenchmark became a V8 Peptides affiliate after the initial evaluation and may earn commission on referred orders. Code BENCHMARK gives shoppers 10% off. The relationship does not change our testing findings or scoring evidence. We checked public product listings and laboratory documents; we did not purchase or independently test a vial. Products are labeled for laboratory research only, not for human or animal consumption. This review evaluates commercial transparency and documentary evidence.
What the laboratory evidence supports
At the October 29 review, the public certificate library contained 13 PDFs. Each printed a sample code and lot number and named V8 Peptides. All resolved through Accumark’s verification service. The laboratory records matched the client, sample code, lot and published peptide purity, and each laboratory PDF was identical to the vendor-hosted copy.
Twelve reports concern peptides. Their reported purity ranged from 98.94% to 99.972%, averaging 99.54%. The other report concerns bacteriostatic water and measures benzyl alcohol at 0.86% v/v; that concentration is excluded from peptide-purity averages.
The documents report identity, HPLC purity, measured content or fill volume, endotoxin testing by LAL, and rapid sterility screening by PCR. PCR screening is not a compendial USP <71> sterility test. No heavy-metal results were observed. These are findings for submitted samples, not proof of the condition of every vial or suitability for human use.
Read the printed compound, nominal size and lot. A certificate for one strength does not establish testing of another strength, and the shorthand TB-500 does not uniquely identify the molecule.
The living vendor profile and V8 Peptides COA records retain current evidence and individual report links.
Catalog and exact tested strengths
The shop listed 27 product pages with 32 labeled size options. We added 29 single-vial prices across 24 comparison groups. Semaglutide 10 mg was sold out, but its report remains part of the public evidence. Bacteriostatic water 10 ml is a support supply and stays outside peptide price-per-milligram comparisons. No spray, capsule, tablet or IU offers were found.
The reports cover 13 exact options across 12 product pages, including water and sold-out semaglutide. Retatrutide has separate reports for its 10 mg and 20 mg options. The GHK-Cu report is for 100 mg; it does not give exact-strength testing credit to 50 mg. Sermorelin’s report similarly concerns the 10 mg option, not 5 mg.
The denominator includes all labeled options, including supplies and unavailable products. Unreported sizes remain visible as coverage gaps. This prevents a partial library from appearing to test the whole catalog.
Fragment identities change the comparison
The Accumark documents for Wolverine, GLOW and KLOW explicitly identify TB500 (17–23 Fragment). We place those blends in their own comparison groups rather than grouping them with full-length thymosin beta-4 blends or Ac-SDKP blends.
November 2, 2026 re-review: The standalone TB-500 page now specifies the acetylated thymosin beta-4 17–23 fragment, Ac-LKKTETQ, with formula C38H68N10O14. This resolves the sequence/formula conflict recorded in our original review. Its current $75 list price for 10 mg is eligible for the separate 17–23 fragment comparison group; it is not full-length thymosin beta-4.
The newly linked ARC-TB10-003 certificate reports the 17–23 fragment, 10 mg nominal size, 10.43 mg measured content and 99.53% HPLC purity, published August 13, 2026. However, both pages name Palmetto Peptides LLC, and Accumark’s exact YZZ4-D6L3 record names the same client. The vendor and laboratory PDFs match byte-for-byte. We preserve it as a third-party-client document, but it adds no V8 verification, tested-strength coverage or scoring credit. A laboratory-confirmed link between that tested lot and V8’s stock, or a V8-named report for its lot, is still needed. The original review figures above describe the October 29 evidence set.
Prices, promotions and fulfillment
The pricing board and Stack Builder now apply the verified 10% BENCHMARK shopper discount to single-vial list prices. At the original catalog check, listed prices were BPC-157 10 mg at $74, GHK-Cu 100 mg at $60, and retatrutide 20 mg at $200. The NAD+ option explicitly labels 1000 mg at $110.
V8 advertised 10% off for email signup and an additional 3% for Zelle or crypto. Those offers remain excluded from comparison prices. After the initial evaluation, the checkout preview accepted BENCHMARK for $7.40 off a $74 BPC-157 vial and $14.80 off two vials. The referral link applies the code. We did not complete a purchase or certify combination with signup, payment-method, sale, or other-code offers. See the current offer page.
The shipping page states U.S.-only fulfillment from Florida, processing in one to two business days, USPS Ground at $7.50 and Priority at $11.50. Card payment is offered through an emailed Stripe invoice; Zelle and crypto are also advertised. These are dated vendor statements, not independently measured delivery performance.
Business identity and external context
The official site identifies V8 Processing LLC and publishes 390 NE 191st St #49862, Miami, FL 33179, with [email protected]. We treat that as a vendor-stated mailing address rather than a verified fulfillment facility. The laboratory client is V8 Peptides.
Our scoped Trustpilot lookup for v8peptides.com found no listing at review time. It contributes no Trustpilot bonus; it is not an adverse customer-review finding. Similarly named brands are not substituted for this domain.
Use the benchmark methodology to understand how the published evidence and catalog coverage contribute to the score. The current profile, COA database, pricing board and official shop provide the changing evidence and availability.
Common questions
Does V8 Peptides publish independently checkable COAs?
Yes. On October 29, 2026, all 13 PDFs in its public library matched the laboratory PDFs byte-for-byte. Accumark's records named V8 Peptides and matched each sample code, lot and published peptide purity. Twelve reports concern peptides and one concerns bacteriostatic water.
Does every V8 Peptides strength have a COA?
No. The catalog had 27 product pages and 32 labeled size options. Reports covered 13 exact options across 12 product pages. Retatrutide 10 mg and 20 mg had separate reports; a GHK-Cu 100 mg report did not establish testing of its 50 mg option.
Are the GLOW, KLOW and Wolverine blends full-length thymosin beta-4 blends?
Their Accumark reports identify the TB500 component as the 17–23 fragment. PeptideBenchmark groups these separately from blends containing full-length thymosin beta-4. On November 2, the standalone page specified Ac-LKKTETQ and a consistent fragment formula. Its price is now compared with the 17–23 fragment. The linked report names Palmetto Peptides LLC, so it adds no V8 testing credit without evidence linking that lot to V8 stock.
Is PeptideBenchmark affiliated with V8 Peptides?
PeptideBenchmark became a disclosed V8 Peptides affiliate on October 29, 2026. Code BENCHMARK gives 10% off, verified by the checkout preview. Commission is separate from shopper savings, and the relationship does not change the evidence findings.